3) In recent years, treatment with immune checkpoint inhibitors, alone or in combination with chemotherapy, has become standard for advanced and recurrent non-small cell lung cancer; therefore, treatment regimens for RET fusion-positive lung cancer patients must be carefully considered. This evidence concerns the gene RET and lung cancer.